PARABDRUGS

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2020.

The Exchange had sought clarification from Parabolic Drugs Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Statement of Cash Flow not submitted The response of the Company is enclosed.

Outcome of Board meeting held on 07.12.2020 for revised unaudited financial results for quarter and half year ended 30.09.2020

The Exchange has sought clarification from Parabolic Drugs Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Statement of Cash Flow not submitted The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2020.

The Exchange has sought clarification from Parabolic Drugs Limited for the quarter ended 30-Jun-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted. -2. Board meeting notice not submitted. The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2020.

Pursuant to Intimation Letter dated 18.08.2020 and Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we furnish herewith the updated Audited Financial Results of the Company for the Quarter and Year ended 31.03.2019. The Meeting was commenced from 11:00 am and concluded at 12:15 pm

The Exchange has sought clarification from Parabolic Drugs Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone audited report not submitted. -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2020.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2019.

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone audited report not submitted. -2. No Segment Reporting. -3. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -4. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2019.

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Board meeting notice not submitted. The response of the Company is awaited.

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone limited review report not submitted The response of the Company is enclosed.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2018.

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted The response of the Company is attached.

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2018.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2018.

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. Standalone Reconciliation of Equity not submitted -3. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -4. Consolidated Reconciliation of profit and los

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. Standalone Reconciliation of Equity not submitted -3. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -4. Consolidated Reconciliation of profit and loss

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Reconciliation of profit and loss not submitted -2. Reconciliation of Equity not submitted The response of the Company is enclosed.

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Reconciliation of profit and loss not submitted -2. Reconciliation of Equity not submitted The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended 30-Sep-2017.

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company was required to clarify the following: -1. Reconciliation of profit and loss not submitted. -2. Financial results not submitted as per Ind-AS format. -3. Financial results not submitted as per Schedule III to the Companies Act, 2013The response of the Company is enclosed.

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company was required to clarify the following: -1. Reconciliation of profit and loss not submitted. -2. Financial results not submitted as per Ind-AS format. -3. Financial results not submitted as per Schedule III to the Companies Act, 2013The response of the Company is enclosed.

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company is required to clarify. -1. Reconciliation of profit and loss not submitted. -2. Financial results not submitted as per Ind-AS format. -3. Financial results not submitted as per Schedule III to the Companies Act, 2013The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2016.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2016.

Parabolic Drugs Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended June 30, 2016.

Parabolic Drugs Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2016.

Parabolic Drugs Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended December 31, 2015.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2015.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2015.

Parabolic Drugs Limited, Parabolic Drugs Limited has submitted to the exchange the standalone & consolidated financial results along with the Auditors Report for the period ended 31-Mar-2015.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Parabolic Drugs Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2013.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2013.

Parabolic Drugs Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2013.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2012.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2012 with Limited Review Report.